About
Feng Ren is a medicinal chemist and biotech executive serving as Executive Director, Co-CEO, and Chief Scientific Officer of Insilico Medicine, where he leads drug discovery and development. Before joining Insilico in 2021, he was senior vice president and head of chemistry and biology at Shanghai Medicilon, and earlier spent 11 years at GlaxoSmithKline in drug discovery, ending as director and head of chemistry in the neurodegeneration DPU. Public sources reviewed did not show a formal role at Propel(x), so that database linkage appears unconfirmed.
Areas of interest
biotechdrug discoveryAI in medicinemedicinal chemistryclinical developmentlongevityaging-related diseasefibrosiscancerimmunologyneurodegeneration